Impact of adjuvant therapy on melanoma-specific survival in elderly patients with high-risk resected melanoma: a multicenter international retrospective study
Open Access
- 7 October 2026
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (10) , e016060
Abstract
Purpose: Adjuvant systemic therapy improves recurrence-free survival in resected high-risk melanoma, but elderly patients remain markedly under-represented in clinical trials; their competing risk of death from other causes needs to be considered. Consequently, the clinical benefit of adjuvant therapy in older populations remains uncertain. We conducted an international real-world study to evaluate survival outcomes of patients aged ≥75 years with resected stage III-IV melanoma managed with adjuvant systemic therapy or observation. Methods: In this multicenter retrospective cohort study, patients aged ≥75 years with completely resected stage III-IV cutaneous melanoma were identified across 14 international melanoma centers. Patients received either standard adjuvant systemic therapy (anti-programmed cell death protein 1 immunotherapy or BRAF/MEK-targeted therapy) or observation. The primary endpoint were melanoma-specific survival (MSS) and overall survival (OS). Secondary endpoints included recurrence-free survival (RFS). Survival outcomes were estimated using Kaplan-Meier methods and evaluated with multivariable Cox regression models adjusted for age, stage, sex, and mutation status. Results: A total of 580 patients were included (median age 79 years; range, 75–99), of whom 222 (38%) received adjuvant therapy and 358 (62%) underwent observation. Adjuvant therapy was associated with significantly improved MSS, with 5-year MSS of 74% compared with 60% in the observation group (adjusted HR 0.58; 95% CI 0.40 to 0.85; p=0.005), as well as OS (adjusted HR 0.66, 95% CI 0.51 to 0.87; p=0.002). Adjuvant therapy was also associated with improved RFS (HR 0.57, 95% CI 0.45 to 0.72; p<0.0001). Among patients managed with observation, disease recurrence occurred in 69%, yet only 47% of those patients received systemic therapy as first-line management of recurrence. Notably, among observation patients who remained recurrence-free or received systemic therapy after recurrence, MSS was comparable to that observed in adjuvant-treated patients (HR 0.83; 95% CI 0.55 to 1.25). Conclusion: In this large international real-world cohort of elderly patients with resected melanoma, adjuvant therapy was associated with clinically meaningful improvements in MSS, OS and RFS. Although immunotherapy retained efficacy when administered at recurrence, many elderly patients did not receive systemic therapy as first-line management of recurrence. Adjuvant therapy may therefore represent an important strategy to ensure timely access to effective treatment in carefully selected older patients.Keywords
This publication has 25 references indexed in Scilit:
- Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREGEuropean Journal of Cancer, 2026
- Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based studyEuropean Journal of Cancer, 2025
- Real‐world experience of adjuvant immunotherapy for stages III–IV melanoma: A monocentric observational studyJEADV Clinical Practice, 2025
- Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 studyAnnals of Oncology, 2024
- Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialEuropean Journal of Cancer, 2024
- Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patientsCancer Immunology, Immunotherapy, 2024
- Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanomaEuropean Journal of Cancer, 2024
- Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialNature Medicine, 2023
- Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With CancerJAMA Oncology, 2021
- Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment RegistryJournal of Geriatric Oncology, 2021